Stocktoria

Prelude Therapeutics Inc PRLD

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-09-25

Prelude Therapeutics Inc statistics & valuation

Market cap$348.8M
P / S28.7×
P / B5.1×
Net margin-819.6%
Return on equity-145.0%
FCF margin-464.3%
Return on capital-118.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-1816.80% -819.60% 2019202020212022202320242025
Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-1995.90% -861.30% 2019202020212022202320242025
Return on equity (%)
-26.80% -39.10% -59.10% -51.40% -96.70% -145.00% 2019202020212022202320242025
Shares outstanding
46.0M 47.4M 60.4M 75.8M 77.0M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-126.10% -25.50% -36.60% -52.40% -43.90% -72.50% -70.40% 2019202020212022202320242025
Free cash flow margin (%)
-1480.70% -464.30% 2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$2.43 -$2.44 -$2.02 -$1.68 -$1.29 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-861.3%-1995.9%—————
Net margin-819.6%-1816.8%—————
FCF margin-464.3%-1480.7%—————
Return on assets-70.4%-72.5%-43.9%-52.4%-36.6%-25.5%-126.1%
Return on equity-145.0%-96.7%-51.4%-59.1%-39.1%-26.8%55.8%
Current ratio1.995.3010.799.4215.3719.414.18

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.